Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Craig

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
European Journal of Pharmacology|July 16, 2003
Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859Yuhong Qiu, Sheela Bhattacharjee, Patricia Kraft, et al.
Journal of Medicinal Chemistry|January 23, 2004
Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitorsJames C Lanter, Zhihua Sui, Mark J Macielag, et al.
Journal of Sleep Research|October 8, 2024
Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 studyYves Dauvilliers, Sonya Elizabeth Craig, Maria R Bonsignore, et al.
Journal of Medicinal Chemistry|January 24, 2003
Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunctionWeiqin Jiang, Zhihua Sui, Mark J Macielag, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
European Journal of Pharmacology|July 16, 2003
Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859Yuhong Qiu, Sheela Bhattacharjee, Patricia Kraft, et al.
Journal of Medicinal Chemistry|January 23, 2004
Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitorsJames C Lanter, Zhihua Sui, Mark J Macielag, et al.
Journal of Sleep Research|October 8, 2024
Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 studyYves Dauvilliers, Sonya Elizabeth Craig, Maria R Bonsignore, et al.
Journal of Medicinal Chemistry|January 24, 2003
Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunctionWeiqin Jiang, Zhihua Sui, Mark J Macielag, et al.
Pageof 4